Unknown

Dataset Information

0

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.


ABSTRACT:

Purpose

Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the landmark trastuzumab adjuvant trials who originally tested HER2-positive but were HER2-negative by central HER2 testing appeared to possibly benefit from trastuzumab. The objective for the NSABP B-47 trial was to determine whether the addition of trastuzumab to adjuvant chemotherapy (CRx) would improve invasive disease-free survival (IDFS) in patients with HER2-negative breast cancer.

Patients and methods

A total of 3,270 women with high-risk primary IBC were randomly assigned to CRx with or without 1 year of trastuzumab. Eligibility criteria included immunohistochemistry (IHC) score 1+ or 2+ with fluorescence in situ hybridization ratio (FISH) < 2.0 or, if ratio was not performed, HER2 gene copy number < 4.0. CRx was either docetaxel plus cyclophosphamide or doxorubicin and cyclophosphamide followed by weekly paclitaxel for 12 weeks.

Results

At a median follow-up of 46 months, the addition of trastuzumab to CRx did not improve IDFS (5-year IDFS: 89.8% with CRx plus trastuzumab [CRxT] v 89.2% with CRx alone; hazard ratio [HR], 0.98; 95% CI, 0.76 to 1.25; P = .85). These findings did not differ by level of HER2 IHC expression, lymph node involvement, or hormone-receptor status. For distant recurrence-free interval, 5-year estimates were 92.7% with CRxT compared with 93.6% for CRx alone (HR, 1.10; 95% CI, 0.81 to 1.50; P = .55) and for overall survival (OS) were 94.8% with CRxT and 96.3% in CRx alone (HR, 1.33; 95% CI, 0.90 to 1.95; P = .15). There were no unexpected toxicities from the addition of trastuzumab to CRx.

Conclusion

The addition of trastuzumab to CRx did not improve IDFS, distant recurrence-free interval, or OS in women with non-HER2-overexpressing IBC. Trastuzumab does not benefit women without IHC 3+ or FISH ratio-amplified breast cancer.

SUBMITTER: Fehrenbacher L 

PROVIDER: S-EPMC7007289 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.

Fehrenbacher Louis L   Cecchini Reena S RS   Geyer Charles E CE   Rastogi Priya P   Costantino Joseph P JP   Atkins James N JN   Crown John P JP   Polikoff Jonathan J   Boileau Jean-Francois JF   Provencher Louise L   Stokoe Christopher C   Moore Timothy D TD   Robidoux André A   Flynn Patrick J PJ   Borges Virginia F VF   Albain Kathy S KS   Swain Sandra M SM   Paik Soonmyung S   Mamounas Eleftherios P EP   Wolmark Norman N  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20191210 5


<h4>Purpose</h4>Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the landmark trastuzumab adjuvant trials who originally tested HER2-positive but were HER2-negative by central HER2 testing appeared to possibly benefit from trastuzumab. The objective for the NSABP B-47 trial was to determine whether the addition of trastuzumab to adjuvant chemotherapy (CRx) would improve invasive  ...[more]

Similar Datasets

| S-EPMC8137688 | biostudies-literature
| S-EPMC6900835 | biostudies-literature
| S-EPMC6695304 | biostudies-literature
| S-EPMC7674704 | biostudies-literature
| S-EPMC5825682 | biostudies-literature
| S-EPMC8979645 | biostudies-literature
| S-EPMC3848987 | biostudies-literature
| S-EPMC5996978 | biostudies-literature
| S-EPMC8903071 | biostudies-literature